BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15305378)

  • 1. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).
    Bonaccorsi L; Carloni V; Muratori M; Formigli L; Zecchi S; Forti G; Baldi E
    Int J Cancer; 2004 Oct; 112(1):78-86. PubMed ID: 15305378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.
    Bonaccorsi L; Muratori M; Carloni V; Marchiani S; Formigli L; Forti G; Baldi E
    Steroids; 2004 Aug; 69(8-9):549-52. PubMed ID: 15288768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The androgen receptor and prostate cancer invasion.
    Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E
    Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling mechanisms that mediate invasion in prostate cancer cells.
    Bonaccorsi L; Marchiani S; Muratori M; Carloni V; Forti G; Baldi E
    Ann N Y Acad Sci; 2004 Dec; 1028():283-8. PubMed ID: 15650253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
    Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
    Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor and prostate cancer invasion.
    Bonaccorsi L; Muratori M; Carloni V; Zecchi S; Formigli L; Forti G; Baldi E
    Int J Androl; 2003 Feb; 26(1):21-5. PubMed ID: 12534934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
    Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
    Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines.
    Bonaccorsi L; Nosi D; Muratori M; Formigli L; Forti G; Baldi E
    J Mol Endocrinol; 2007 Feb; 38(1-2):51-66. PubMed ID: 17242169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype.
    Bonaccorsi L; Carloni V; Muratori M; Salvadori A; Giannini A; Carini M; Serio M; Forti G; Baldi E
    Endocrinology; 2000 Sep; 141(9):3172-82. PubMed ID: 10965888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
    Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
    Tørring N; Jørgensen PE; Sørensen BS; Nexø E
    Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
    Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
    Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
    Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
    Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
    van der Poel HG
    Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor and invasion in prostate cancer.
    Hara T; Miyazaki H; Lee A; Tran CP; Reiter RE
    Cancer Res; 2008 Feb; 68(4):1128-35. PubMed ID: 18281488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
    Xie Y; Wolff DW; Lin MF; Tu Y
    Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.